GSKH.US Precidian ETFs Trust - GSK plc ADRhedged
- Total assets
- 716K
- Expense ratio
- -
- Dividend yield
- 2.94%
- 1-year return
- +6.49%
- Holdings
- 1
- Since
- 2025
Fund data as reported by the issuer, updated Nov 15, 2026. Total assets are in the fund's base currency.
What does GSKH.US invest in?
- Mostly Non-US stocks (99.9%)
- Largest sector: Healthcare (100.0%)
- Largest region: United Kingdom (100.0%)
- Top 3 holdings: 98.7% of the fund
Asset allocation
- Non-US stocks 99.9%
- Cash 4.0%
Top holdings
- GSK plc 98.65%
Precidian ETFs Trust - GSK plc ADRhedged performance
Sharpe ratio 0.00- This year
- +6.81%
- 1 year
- +6.49%
- 3 years
- -
- 5 years
- -
Volatility 23.2% over 1 year. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
GSKH.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About Precidian ETFs Trust - GSK plc ADRhedged
The series, under normal circumstances, invests at least 95% of its net assets in American Depositary Receipts ("ADRs") of GSK plc (the "Company"). The series will not invest directly in the company. The fund is non-diversified.
Full fund profilePrecidian ETFs Trust - GSK plc ADRhedged top holdings
98.7% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| GSK plc GSK.US | Healthcare | United States | 98.65% |
GSKH.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
GSKH.US regional exposure
- United Kingdom100.0%
Share of the stocks in the fund.
Company size
Average market cap 98.9B- Mega cap99.9%
Precidian ETFs Trust - GSK plc ADRhedged fund profile
- Fund name
- Precidian ETFs Trust - GSK plc ADRhedged
- Ticker
- GSKH.US
- Exchange
- USA Stocks
- Issuer
- ADRH
- Index tracked
- -
- Category
- Healthcare Equity
- Inception date
- Jan 6, 2025
- Trading currency
- USD
- Expense ratio
- -
About Precidian ETFs Trust - GSK plc ADRhedged
The series, under normal circumstances, invests at least 95% of its net assets in American Depositary Receipts ("ADRs") of GSK plc (the "Company"). The series will not invest directly in the company. The fund is non-diversified.